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Abstract
Goals of work The goals of the study were to determine the
occurrence rates for and the severity of symptoms at the
middle, end, and 1 month after the completion of radiation
therapy (RT), to determine the number and types of
symptom clusters at these three time points, and to evaluate
for changes over time in these symptom clusters.
Materials and methods Symptom occurrence and severity
were evaluated using the Memorial Symptom Assessment
Scale (MSAS) in a sample of patients (n=160) who
underwent RT for breast or prostate cancer. At each time
point, an exploratory factor analysis was done to determine
the number of symptom clusters (i.e., symptom factors)
based on the MSAS symptom severity ratings.
Main results The majority of the patients were male and
married with a mean age of 61.1 years. The five symptoms
with the highest occurrence rates across all three time
points were lack of energy, pain, difficulty sleeping, feeling
drowsy, and sweats. Although the number of symptoms and
the specific symptoms within each symptom cluster were
not identical across the three time points, three relatively
similar symptom clusters (i.e., “mood-cognitive” symptom
cluster, “sickness-behavior” symptom cluster, “treatment-
related”, or “pain” symptom cluster) were identified in this
sample. The internal consistency coefficients for the mood-
cognitive symptom cluster and sickness-behavior symptom
cluster were adequate at ≥0.68.
Conclusions Three relatively stable symptom clusters were
found across RT. The majority of the symptom cluster
severity scores were significantly higher in patients with
breast cancer compared to patients with prostate cancer.
Keywords Symptom clusters . Exploratory factor analysis .
Breast cancer . Prostate cancer . Radiation therapy .
Sickness behavior
Introduction
The majority of the research on symptom clusters is cross-
sectional in nature and has evaluated heterogeneous
samples of patients in terms of cancer diagnoses and
treatments as well as at different time points in their disease
and treatment trajectory (for reviews, see [2, 8, 15]). Only a
limited number of studies have evaluated how symptom
clusters change over the course of chemotherapy or
radiation therapy (RT) [1, 5–7, 9–12, 14, 24]. Among these
studies, four reported no changes in symptom clusters
[9, 10, 14, 24], while six identified differences in the
symptom clusters over time [1, 5–7, 11, 12]. These
inconsistent findings may relate to differences in the
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methods of data collection and/or analyses or to actual
differences in patients' symptoms as a result of their disease
or treatments.
For example, in these longitudinal studies, the instru-
ments used to measure symptoms and the number of
symptoms on each instrument are highly variable. While
three studies [7, 9, 24] used comprehensive symptom
inventories (i.e., Symptom Checklist of 32 Symptoms,
the Edmonton Symptom Assessment System, M. D.
Anderson Symptom Inventory) and evaluated symptom
severity, the other studies used symptom specific measures
or symptom subscales from a quality of life questionnaire
[1, 5, 6, 10–12, 14].
In addition, several analytic methods were used to determine
the symptom clusters. In three studies that evaluated for
changes over time in the magnitude of the correlations among
symptoms, a number of symptoms were only moderately
correlated with other symptoms. However, the strength of these
correlations changed over time [1, 5, 6]. In contrast, in studies
that used factor analysis to identify changes in symptom
clusters [7, 9, 10, 14], the findings are inconsistent.
In a study of lung cancer patients [9], a single cluster of
seven symptoms was identified at diagnosis, and this
cluster did not change at 3 and 6 months after diagnosis.
In another study of breast cancer patients who were
receiving chemotherapy or RT [14], two distinct symptom
clusters were identified, and these clusters were generally
stable across the treatment trajectories. In a study of
patients who underwent RT for brain metastasis [7], three
symptom clusters were identified at five different time
points during RT. Of note, the specific symptoms within
each cluster did change over time. Finally, in a longitudinal
study of patients with brain tumors who underwent RT
[10], the two symptom clusters that were identified at the
beginning of RT did not change over the course of RT.
The question of whether symptom clusters are stable or
change over time is important both for clinical practice and
for the science of symptom cluster research. Given the
paucity of research on changes in symptom clusters over
time, the purposes of this study, in a sample of patients who
underwent RT, were to determine the occurrence and
severity of symptoms at the middle, end, and 1 month after
the completion of RT, to determine the number and types of
symptom clusters at these three time points, and to evaluate
for changes over time in these symptom clusters.
Materials and methods
Participants and settings
This study is part of a descriptive, longitudinal study that
evaluated the trajectories of fatigue, pain, and sleep
disturbances in oncology outpatients over the course of
RT. Patients (n=160) were included if they were adults
(>18 years of age) who were able to read, write, and
understand English, had a Karnofsky Performance Status
(KPS) score of >60, and were scheduled to receive primary
or adjuvant RT. Patients were excluded if they had
metastatic disease, had more than one cancer diagnosis, or
had a diagnosed sleep disorder. Patients were recruited from
RT departments located in a Comprehensive Cancer Center
and a community-based oncology program. This study was
approved by the Human Subjects Committee at the
University of California, San Francisco and at the second
study site.
Study procedures
At the time of the simulation visit (i.e., approximately
1 week prior to the start of RT), patients were approached
by a research nurse to discuss participation in the study.
After obtaining written informed consent, they were asked
to complete a number of baseline questionnaires and
symptom inventories. Additional assessments were done
over the course of RT and for 4 months after the completion
of RT. Demographic and clinical data, as well as data from
the Memorial Symptom Assessment Scale (MSAS) [21]
that were obtained at the middle, end, and 1 month after the
completion of RT, were used in these analyses.
Instruments
A demographic questionnaire provided information on
age, gender, marital status, education, ethnicity, and
employment status. Patients completed a checklist of co-
morbidities and the KPS scale [13]. The KPS is widely
used to evaluate the functional status of cancer patients
and has well-established validity and reliability [16].
Patients' medical records were reviewed for disease and
treatment information.
The MSAS is a self-report questionnaire designed to
measure the multidimensional experience of symptoms
[21]. The MSAS contains a list of 32 physical and
psychological symptoms that occur as a result of cancer
or cancer treatment. Using the MSAS, patients were asked
to indicate whether or not they had experienced each
symptom in the past week (i.e., symptom occurrence). If
they had experienced the symptom, they were asked to
rate its severity, frequency of occurrence, and distress.
Symptom severity was measured using a five-point Likert
scale (i.e., 0=not at all, 1=mild, 2=moderate, 3=severe,
4=very severe). The patients' responses to the severity
items were used to create the symptom clusters at the three
time points. The reliability and validity of the MSAS is
well established [21].
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Data analysis
All analyses were done using SPSS Version 15 and MPlus
version 5.0 [19]. Prior to the symptom cluster analyses,
appropriate descriptive statistics were used to generate
information on the patients' demographic and clinical
characteristics, as well as on symptom occurrence and
severity.
At each of the three time points, an exploratory factor
analysis (EFA) was performed to determine the number of
symptom clusters based on symptom severity ratings.
While it is more accurate to describe the results of the
EFAs as “symptom factors”, in this paper, the term
symptom cluster will be used to describe the results of the
EFAs. In order to have sufficient variation in the data to
perform the EFAs at each time point, symptoms that were
present in ≥20% but not more than 80% of the patients
were used in these analyses. While this approach resulted in
different numbers of symptoms being included in each
EFA, it took into consideration the fact that as patients
progress through RT, the occurrence and severity of specific
symptoms may change over time.
The major decisions in factor analysis include how to
estimate communality, how to determine the number of
factors, and how to determine the method for rotating the
factors to obtain the simple structure. Polychoric correla-
tions were used to create the matrix of associations because
the MSAS items are measured with an ordinal categorical
scale [4, 18]. The simple structure was estimated using the
method of robust unweighted least squares with geomin
(oblique) rotation. The robust unweighted least squares
estimator was chosen to achieve more reliable results
because of the relatively small sample size (i.e., <200)
[17, 18].
For each EFA, polychoric correlations were used to
create the matrix of associations among 14 symptoms at
Time 1 (i.e., middle of RT), among 13 symptoms at Time 2
(i.e., end of RT), and among 12 symptoms at Time 3 (i.e.,
1 month after the completion of RT). Factor loadings were
considered meaningful if they exceeded 0.30 [4, 20, 26].
The number of factors was considered sufficient to explain
the symptom correlations if the model's Chi square was not
significant, its comparative fit index (CFI) was ≥0.95, and
the root mean square error of approximation (RMSEA) was
≤0.06 [22]. It is possible when using oblique rotation for
two items to load on the same factor. If this situation
occurred, a particular symptom was included in a factor
based on clinical or theoretical plausibility.
While similarities and differences among the symptom
clusters found at Times 1, 2, and 3 were examined, no
statistical analyses were performed because the best factor
structure at each time point was different. For each time
point, differences in severity scores (calculated as the mean
rating of the items within each symptom cluster) for each of
the symptom clusters between patients with breast and
prostate cancer were evaluated using the Mann–Whitney
two sample rank-sum test. All calculations used actual
values. Adjustments were not made for missing data.
Therefore, the cohort for each analysis was dependent on
the largest set of available data. Differences were considered
statistically significant at the p<0.05 level.
Results
Demographic and clinical characteristics
The demographic characteristics of the patients (n=160)
at the time of the simulation visit are summarized in
Table 1. The majority of the patients were male and
married, with a mean age of 61.1 (SD=11.5) years. The
majority of the patients were Caucasian (72.8%) and well
educated (16.1±2.9 years of education).
The clinical characteristics of the sample are summarized
in Table 2. Over half of the patients had prostate cancer.
Almost all of the breast cancer patients (90.9%) had
undergone surgery prior to RT compared to only 9.8% of
the patients with prostate cancer. The mean KPS score for
Table 1 Demographic characteristics of the sample (n=160)
Characteristic Mean (SD)
Age (years) 61.1 (11.5)
Education (years) 16.1 (2.9)
n (%)
Gender
Female 78 (48.7)
Male 82 (51.3)
Ethnicity
Caucasian–White 115 (72.8)
African American 25 (15.8)
Asian or Pacific islander 9 (5.7)
Hispanic 4 (2.5)
Other 5 (3.2)
Marital status
Married/partnered 80 (51.0)
Separated or divorced 33 (21.0)
Never married 27 (17.2)
Widowed 9 (5.7)
Not married but living together 8 (5.1)
Employment status
Employed 69 (44.5)
Unemployed 86 (55.5)
SD standard deviation
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the sample was 92.4 (SD=9.7), the mean number of
comorbid conditions was 4.9 (SD=2.5), and the types of
comorbid conditions were diverse.
Occurrence and severity of symptoms at each time point
The occurrence rates for the symptoms that occurred in
≥20% of the patients at each time point are summarized in
Table 3. Across all three time points, the most prevalent
symptom was lack of energy, followed by pain, difficulty
sleeping, feeling drowsy, and sweats. The mean number of
symptoms per patient at the middle, end, and 1 month after
the completion of RT was 6.5 (SD=5.3), 6.0 (SD=4.7), and
5.9 (SD=5.2), respectively. Overall, about 20% of patients
experienced ≥10 symptoms concurrently across all three
time points.
The mean severity scores for each symptom at each time
point are listed in Table 3. Symptom severity was analyzed
by averaging the symptom severity scores for the patients
who had the symptom. Lack of energy, difficulty sleeping,
sweats, and problem with urination were the four most
severe symptoms at all three time points.
Symptom clusters at the middle of RT (Time 1; n = 152)
As shown in Table 4, 14 symptoms were included in EFA
at Time 1. A three-factor solution indicated a good fit
Table 2 Clinical characteristics of the sample (n=160)
Characteristic Mean (SD)
Mean number of comorbid conditions 4.9 (2.5)
Karnofsky Performance Status Score 92.4 (9.7)
Total dose of radiation administered (cGy) 6299.1 (1020.1)
n (%)
Diagnosis
Breast cancer 78 (48.7)
Prostate cancer 82 (51.3)
Previous cancer treatment
Surgery
Lumpectomy 57 (74.0)
Partial mastectomy 9 (11.7)
Simple mastectomy 4 (5.2)
Prostatectomy 8 (9.8)
Chemotherapy 43 (55.8)
Hormonal therapy 74 (46.3)
Five most common comorbid conditions
Back problems 52.8%
Allergies 47.7%
Arthritis 35.5%
Hemorrhoids 34.4%
Headaches 32.5%
SD standard deviation
Table 3 Occurrence and severity rates for symptoms at each time point
Symptoms Middle of RT (n=152) End of RT (n=160) 1 month after the completion of RT (n=132)
% M (SD) % M (SD) % M (SD)
Lack of energy 55.2 1.83 (0.66) 59.4 1.96 (0.73) 51.6 1.85 (0.69)
Pain 50.3 1.78 (0.75) 51.8 1.83 (0.76) 39.8 1.93 (0.64)
Difficulty sleeping 47.2 1.90 (0.83) 47.1 1.99 (0.81) 47.2 1.80 (0.85)
Feeling drowsy 51.0 1.59 (0.59) 44.4 1.86 (0.68) 44.7 1.61 (0.67)
Sweats 42.5 2.00 (0.75) 39.9 1.97 (0.75) 36.4 1.92 (0.81)
Problems with urination 35.7 1.96 (0.59) 37.1 1.91 (0.76) 35.4 1.84 (0.74)
Difficulty concentrating 38.1 1.48 (0.64) 35.9 1.55 (0.69) 31.3 1.59 (0.72)
Feeling irritable 34.7 1.54 (0.61) 34.0 1.67 (0.71) 37.1 1.62 (0.64)
Itching 27.0 1.63 (0.58) 31.9 1.90 (0.78) 13.6 1.59 (0.71)
Worrying 31.0 1.74 (0.68) 29.7 1.89 (0.89) 30.5 1.74 (0.76)
Feeling sad 29.9 1.76 (0.86) 26.9 1.74 (0.79) 29.8 1.72 (0.66)
Cough 17.6 1.81 (0.98) 22.3 1.75 (0.76) 14.4 1.63 (0.60)
Changes in skin 24.5 1.67 (0.61) 20.0 2.24 (0.83) 12.2 1.65 (0.79)
Feeling nervous 20.0 1.72 (0.65) 18.4 1.68 (0.67) 20.0 1.70 (0.64)
Numbness/tingling in hands/feet 18.9 1.74 (0.63) 16.5 1.80 (0.76) 20.3 1.79 (0.57)
Diarrhea 25.5 1.76 (0.64) 17.1 1.67 (0.64) 9.1 1.36 (0.67)
Severity scores range from 1 (mild) to 4 (very severe)
SD standard deviation
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between the data and the model (i.e., χ2=29.7, p=0.19,
CFI=0.99, RMSEA=0.04). Seven symptoms were loaded
on Factor 1: five psychological symptoms (i.e., difficulty
concentrating, feeling sad, feeling nervous, worrying,
feeling irritable) and two skin symptoms (i.e., itching,
changes in skin). Factor 1 was named the “mood-cognitive”
symptom cluster. While itching loaded on the first factor,
this symptom was not included in this symptom cluster
because it was not related to the other symptoms in the
cluster (i.e., correlations between itching and the other
symptoms in the cluster ranged from only 0.12 to 0.22).
However, changes in skin were retained in the cluster
because its correlation with other symptoms in the cluster
ranged from 0.18 to 0.32. For the five psychological
symptoms within Factor 1, the symptoms were moderately
correlated with each other in the range of 0.49 to 0.82.
Factor 2 contained five symptoms (i.e., pain, lack of
energy, feeling drowsy, difficulty sleeping, sweats) and was
named the “sickness-behavior” symptom cluster. The third
factor contained only two symptoms (i.e., diarrhea, problem
with urination) and was named the “treatment-related”
symptom cluster.
For the mood-cognitive symptom cluster, the inter-item
correlations ranged from 0.18 to 0.82 and the Cronbach's
alpha was 0.84. For the sickness-behavior symptom cluster,
the inter-item correlations ranged from 0.14 to 0.63 and the
Table 4 Factor structure at the middle of radiation therapy (N=152)
Symptoms Factor 1 (mood-cognitive symptom) Factor 2 (sickness-behavior symptom) Factor 3 (treatment-related symptom)
Difficulty concentrating 0.55 0.44 0.03
Feeling nervous 0.83 0.03 0.08
Feeling sad 0.53 0.48 −0.01
Worrying 0.66 0.29 −0.02
Itching 0.55 −0.12 −0.23
Feeling irritable 0.70 0.02 0.33
Changes in skin 0.73 −0.12 −0.35
Pain −0.06 0.47 0.08
Lack of energy 0.30 0.65 −0.01
Feeling drowsy 0.44 0.49 0.04
Difficulty sleeping −0.02 0.54 0.00
Sweats 0.03 0.60 −0.16
Problem with urination 0.00 −0.32 1.16
Diarrhea 0.02 −0.09 0.62
Extraction method: robust unweighted least squares; rotation method: geomin (oblique) rotation
Table 5 Factor structure at the end of radiation therapy (N=160)
Symptoms Factor 1 (mood-cognitive symptom) Factor 2 (sickness-behavior symptom) Factor 3 (treatment-related symptom)
Difficulty concentrating 0.55 0.34 0.06
Feeling sad 0.68 0.32 −0.01
Worrying 0.95 0.00 −0.12
Itching 0.37 0.17 0.26
Feeling irritable 0.83 −0.09 −0.02
Pain −0.01 0.58 0.20
Lack of energy 0.10 0.84 −0.04
Feeling drowsy 0.00 1.1 −0.62
Difficulty sleeping 0.25 0.44 0.06
Sweats 0.17 0.34 0.18
Problems with urination 0.13 −0.01 −0.61
Changes in skin 0.48 0.00 0.75
Extraction method: robust unweighted least squares; rotation method: geomin (oblique) rotation
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Cronbach's alpha was 0.68. For the treatment-related
symptom cluster, the inter-item correlation was 0.47 and
the Cronbach's alpha was 0.63.
Symptom clusters at end of RT (Time 2; n= 160)
As shown in Table 5, 12 symptoms were included in the
EFA at Time 2. A three-factor solution indicated a good fit
between the data and the model (i.e., χ2=24.6, p=0.22,
CFI=0.99, RMSEA=0.04). The five symptoms in Factor 1
(i.e., difficult concentrating, feeling sad, worrying, itching,
feeling irritable) were named the mood-cognitive symptom
cluster. The five symptoms in Factor 2 (i.e., pain, lack of
energy, feeling drowsy, difficulty sleeping, sweats) were
named the sickness-behavior symptom cluster. The two
symptoms in Factor 3 (i.e., problem with urination, changes
in skin) were named the treatment-related symptom cluster.
For the mood-cognitive symptom cluster, the inter-item
correlations ranged from 0.23 to 0.65 and the Cronbach's
alpha was 0.78. For the sickness-behavior symptom cluster,
the item total correlations ranged from 0.16 to 0.64 and the
Cronbach's alpha was 0.73. For the treatment-related
symptom cluster (two items), the inter-item correlation
was 0.22 (after reverse coding “problem with urination”)
and the Cronbach's alpha was 0.36.
Symptom clusters at 1 month after completion of RT
(Time 3; n= 132)
As shown in Table 6, 12 symptoms were used in the EFA at
Time 3. A three-factor solution indicated a good fit between
the data and the model (i.e., χ2=23.3, p=0.22, CFI=0.98,
RMSEA=0.04). Factor 1 included four symptoms (i.e.,
difficulty concentrating feeling nervous, feeling sad, worrying)
and was named as mood-cognitive symptom cluster. The
second factor consisted of five symptoms (i.e., lack of energy,
feeling drowsy, difficulty sleeping, problems with urination,
feeling irritable) and was named the sickness-behavior
symptom cluster. While problem with urination loaded on
this factor, this symptom was not included in the symptom
factor because it was not related to the other four symptoms.
The third factor contained the symptoms of pain, numbness/
tingling in hands/feet, and sweats and was named the “pain”
symptom cluster. While sweats loaded on this factor, this
symptom was not included in the symptom cluster because it
was not conceptually related to the other two symptoms.
For the mood-cognitive symptom cluster, the inter-item
correlations ranged from 0.42 to 0.62 and the Cronbach's
alpha was 0.81. For the sickness-behavior symptom cluster,
the inter-item correlations ranged from 0.24 to 0.53 and the
Cronbach's alpha was 0.70. For the pain symptom cluster,
the inter-item correlation was 0.31 and the Cronbach's alpha
was 0.46.
The similarities and dissimilarities in the symptom clusters
across time
The specific symptoms within each symptom cluster at the
three time points are summarized in Table 7. Three distinct
symptom clusters were found across the three time points:
mood-cognitive symptom cluster, sickness-behavior symp-
tom cluster, and treatment-related or pain symptom cluster.
Although the number and specific symptoms within each
cluster are not identical, similarities exist in the mood-
cognitive and sickness-behavior symptom cluster. However,
differences over time were noted in the treatment-related or
Table 6 Factor Structure at 1 month after the completion of radiation therapy (n=132)
Symptoms Factor 1 (mood-cognitive symptom) Factor 2 (sickness-behavior symptom) Factor 3 (pain symptom)
Difficulty concentrating 0.60 0.26 −0.01
Feeling nervous 0.82 0.02 0.04
Feeling sad 0.90 −0.08 −0.01
Worrying 0.81 0.13 −0.04
Lack of energy −0.01 0.71 0.27
Feeling drowsy 0.01 0.83 −0.00
Difficulty sleeping 0.10 0.37 0.12
Problems with urination −0.49 0.42 0.07
Feeling irritable 0.28 0.51 0.06
Pain −0.11 0.16 0.49
Numbness/tingling in hands/feet 0.00 −0.01 1.02
Sweats 0.06 0.31 0.42
Extraction method: robust unweighted least squares; rotation method: geomin (oblique) rotation
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pain symptom clusters. Specifically, at the middle of RT,
problem with urination and diarrhea clustered together,
while problem with urination and skin problems associated
with treatment clustered together at the end of RT.
Furthermore, a new symptom cluster of pain emerged at
1 month after completion of RT.
To determine the validity of the symptom clusters,
differences in symptom severity scores, at each time point,
between patients with breast and prostate cancer were
evaluated using the Mann–Whitney U test. As shown in
Table 8, at every time point and for every symptom cluster
except the treatment-related symptom cluster at the middle
of RT (i.e., problem with urination, diarrhea), the patients
with breast cancer reported significantly higher symptom
cluster severity scores than the patients with prostate
cancer.
Discussion
To our knowledge, this study is the first to describe the
occurrence rates and severity scores for the most common
symptoms experienced by patients over the course of RT as
well as changes over time in symptom clusters in these
patients. Of note, lack of energy, pain, and difficulty
sleeping were the most prevalent symptoms reported by
patients at the middle, the end, and 1 month after the
completion of RT. This finding is consistent with previous
Table 7 Symptom clusters and reliability estimates across time points
Middle of RT End of RT 1month after the completion of RT
Mood-cognitive symptom cluster Difficulty concentrating Difficulty concentrating Difficulty concentrating
Feeling sad Feeling sad Feeling sad
Worrying Worrying Worrying
Feeling irritable Feeling irritable
Feeling nervous Feeling nervous
Itching
Changes in skin
Cronbach's alpha 0.84 0.78 0.81
Sickness-behavior symptom cluster Pain Pain
Lack of energy Lack of energy Lack of energy
Feeling drowsy Feeling drowsy Feeling drowsy
Difficulty sleeping Difficulty sleeping Difficulty sleeping
Sweats Sweats Feeling irritable
Cronbach's alpha 0.68 0.73 0.70
Treatment-related or pain symptom cluster Problem with urination Problem with urination Pain
Diarrhea Changes in skin Numbness/tingling in hands/feet
Cronbach's alpha 0.63 0.36 0.46
Table 8 Differences in the mean symptom severity scores for the three symptom clusters between patients with breast and prostate cancer
Symptom cluster Patient group Middle of RT End of RT 1month after the completion of RT
M (SD) p valuea i (SD) p valuea M (SD) p valuea
Mood-cognitive Breast cancer 0.68 (0.61) 0.000 0.67 (0.61) 0.000 0.67 (0.76) 0.000
Prostate cancer 0.28 (0.51) 0.31 (0.49) 0.22 (0.40)
Sickness-behavior Breast cancer 1.00 (0.64) 0.002 1.02 (0.67) 0.000 0.87 (0.68) 0.007
Prostate cancer 0.66 (0.60) 0.53 (0.55) 0.53 (0.55)
Treatment-related or pain Breast cancer 0.12 (0.35) 0.000 2.40 (0.55) 0.000 0.87 (0.69) 0.02
Prostate cancer 0.97 (0.83) 1.39 (0.48) 0.38 (0.53)
M mean symptom severity score, SD standard deviation, RT radiation therapy
aMann–Whitney U test
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reports of fatigue in patients who underwent RT and
chemotherapy [3, 7, 23]. In addition, lack of energy,
difficulty sleeping, sweats, and problem with urination
were the most severe symptoms at all time points.
However, while the occurrence rate for pain decreased over
time, the severity of pain appeared to increase over time.
Additional research is needed to determine the specific
etiologies for the pain.
Another interesting finding is the relatively high occur-
rence rate for sweats, as well as its relatively high severity
rating compared to other symptoms. Previous studies that
used the MSAS reported that sweats occurred in 33.6% [25]
to 40.0% [21] of patients with a severity rating of 1.67
(SD=0.83) [25]. The relatively high occurrence rates and
severity scores for sweats in this sample may be associated
with biologically or chemically induced menopause in both
the patients with breast and prostate cancer. In fact, across
the three measurement times, 24.3% to 32.1% of the men
and 55.2% to 58.0% of women in this study reported
sweats. This finding warrants additional investigation.
Although the numbers as well as the specific symptoms
within each symptom cluster were not identical across the
three time points, three relatively similar symptom clusters
(i.e., mood-cognitive symptom cluster, sickness-behavior
symptom cluster, treatment-related or pain symptom cluster)
were found over time. Of note, both the mood-cognitive
symptom cluster [7, 10] and the sickness-behavior symptom
cluster [7, 24] were found in other studies of patients who
underwent RT. For example, in a longitudinal study of
patients with brain metastasis who underwent to RT [7], the
symptoms of anxiety and depression clustered together over
the course of RT (i.e., five measures). In addition, in a study
of patients with brain tumors [10], the symptoms of feeling
nervous, feeling sad, and depressed mood formed a mood
cluster at both the beginning and the end of RT.
The symptoms within the sickness-behavior symptom
cluster found in this study were relatively stable over time.
In fact, lack of energy, feeling drowsy, and difficulty
sleeping were present at all three time points. The stability
of these three symptoms is consistent with two previous
longitudinal RT studies [7, 24] and suggests that these
symptoms require systematic assessment and management
in patients who undergo RT. Of note, the internal
consistency coefficients for this symptom cluster were
consistently high across the three time points (i.e.,
Cronbach's alphas ranged from 0.68 to 0.70) in this study
as well as in the study by Chow and colleagues [7]
(Cronbach's alphas ranged from 0.65 to 0.77).
A unique finding in this study is the treatment-related or
pain symptom cluster that changed over time. At the middle
of RT, the treatment-related symptom cluster consisted of
the symptoms of diarrhea and problem with urination.
Further examination of the data demonstrated that both of
these symptoms occurred with a higher frequency in the
patients with prostate cancer compared to those with breast
cancer (i.e., problem with urination=65.3% versus 5.6%
χ2=55.43, p<0.0001; diarrhea=40.5% versus 8.6%; χ²=
19.92, p<0.0001). At the end of RT, the treatment-related
symptom cluster consisted of problem with urination and
changes in skin. At this time point, 70% of the men
reported a problem with urination compared to only 4.3%
of women (χ²=64.74, p<0.0001). In contrast, 43.1% of the
women reported changes in skin compared to only 4.0%
(χ²=29.24, p<0.0001) of the men, respectively. Finally,
1 month after the completion of RT, a new symptom cluster
of pain and numbness/tingling in hands/feet was identified.
All of these symptoms occurred more frequently in the
women with breast cancer than in the men with prostate
cancer (i.e., pain=50% versus 32.4%; χ²=4.02, p=0.045;
numbness/tingling=32.7% versus 11.0%; χ²=9.183, p=
0.002). Taken together, these findings suggest that future
studies of symptom clusters in patients undergoing RT may
need to be done within cancer diagnoses to better determine
treatment-related symptom clusters.
Several limitations of this study need to be mentioned.
The sample size was relatively small and did not allow for
separate evaluations of symptom clusters in patients with
breast and prostate cancer. In addition, as with other
longitudinal studies, dropouts occurred over time. There-
fore, the sample size for each analysis was different. In
addition, because the prevalence rates for the various
symptoms changed overtime, different symptoms were
entered into the various EFAs. Some of these limitations
may be overcome with large samples of patients.
Despite these limitations, the findings from this study
suggest that a mood-cognitive and a sickness-behavior
symptom clusters occur in patients during the course of RT.
However, the specific symptoms within two symptom
clusters were not consistent over time. This finding
suggests that the need for the symptom cluster to remain
stable over time may not be an essential element of the
definition of a symptom cluster. This finding warrants
replication in future longitudinal studies. In addition,
treatment-related symptom clusters that appear to be
diagnosis specific warrant additional investigation.
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